1. Home
  2. VIGL vs WIMI Comparison

VIGL vs WIMI Comparison

Compare VIGL & WIMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIGL
  • WIMI
  • Stock Information
  • Founded
  • VIGL 2020
  • WIMI 2015
  • Country
  • VIGL United States
  • WIMI China
  • Employees
  • VIGL N/A
  • WIMI N/A
  • Industry
  • VIGL Biotechnology: Pharmaceutical Preparations
  • WIMI Computer Software: Prepackaged Software
  • Sector
  • VIGL Health Care
  • WIMI Technology
  • Exchange
  • VIGL Nasdaq
  • WIMI Nasdaq
  • Market Cap
  • VIGL 89.3M
  • WIMI 94.3M
  • IPO Year
  • VIGL 2022
  • WIMI 2020
  • Fundamental
  • Price
  • VIGL $2.80
  • WIMI $1.03
  • Analyst Decision
  • VIGL Strong Buy
  • WIMI
  • Analyst Count
  • VIGL 5
  • WIMI 0
  • Target Price
  • VIGL $21.00
  • WIMI N/A
  • AVG Volume (30 Days)
  • VIGL 2.7M
  • WIMI 4.2M
  • Earning Date
  • VIGL 03-25-2025
  • WIMI 01-01-0001
  • Dividend Yield
  • VIGL N/A
  • WIMI N/A
  • EPS Growth
  • VIGL N/A
  • WIMI N/A
  • EPS
  • VIGL N/A
  • WIMI N/A
  • Revenue
  • VIGL N/A
  • WIMI $84,137,968.00
  • Revenue This Year
  • VIGL N/A
  • WIMI N/A
  • Revenue Next Year
  • VIGL N/A
  • WIMI N/A
  • P/E Ratio
  • VIGL N/A
  • WIMI N/A
  • Revenue Growth
  • VIGL N/A
  • WIMI 19.25
  • 52 Week Low
  • VIGL $1.49
  • WIMI $0.63
  • 52 Week High
  • VIGL $6.06
  • WIMI $2.92
  • Technical
  • Relative Strength Index (RSI)
  • VIGL 71.42
  • WIMI 50.65
  • Support Level
  • VIGL $2.54
  • WIMI $0.86
  • Resistance Level
  • VIGL $2.88
  • WIMI $0.92
  • Average True Range (ATR)
  • VIGL 0.20
  • WIMI 0.07
  • MACD
  • VIGL 0.03
  • WIMI 0.02
  • Stochastic Oscillator
  • VIGL 89.73
  • WIMI 80.00

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

About WIMI WiMi Hologram Cloud Inc.

WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings primarily consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.

Share on Social Networks: